Patents by Inventor Stephen F. Olmstead

Stephen F. Olmstead has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9579353
    Abstract: The invention provides a method and composition for ameliorating or reducing the symptoms, signs, and markers and for the treatment of irritable bowel syndrome, inflammatory bowel disease or gastritis in a mammal in need thereof, said method comprising administering effective amounts of a pharmaceutically acceptable composition containing at least one probiotic microorganism strain comprising Pediococcus for a time sufficient to ameliorate, reduce or treat at least one symptom, sign, or marker of irritable bowel syndrome, inflammatory bowel disease or gastritis.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: February 28, 2017
    Assignee: PROTHERA, Inc.
    Inventor: Stephen F. Olmstead
  • Patent number: 9387236
    Abstract: The invention provides a method and compositions for treating a subject with a lysosomal storage disease such as gaucher disease, by administering to a subject with a lysosomal storage disease a therapeutically effective amount of composition comprising at least one of a protease or peptidase in an amount sufficient to ameliorate, reduce or improve at least one symptom of the disease. The invention also provides dietary supplements for subjects having lysosomal storage diseases.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: July 12, 2016
    Assignee: PROTHERA Inc.
    Inventor: Stephen F. Olmstead
  • Publication number: 20120315263
    Abstract: The invention provides a method and compositions for treating a subject with a lysosomal storage disease such as gaucher disease, by administering to a subject with a lysosomal storage disease a therapeutically effective amount of composition comprising at least one of a protease or peptidase in an amount sufficient to ameliorate, reduce or improve at least one symptom of the disease. The invention also provides dietary supplements for subjects having lysosomal storage diseases.
    Type: Application
    Filed: June 10, 2011
    Publication date: December 13, 2012
    Inventor: Stephen F. Olmstead
  • Publication number: 20120315249
    Abstract: The invention provides a method and composition for ameliorating or reducing the symptoms, signs, and markers and for the treatment of irritable bowel syndrome, inflammatory bowel disease or gastritis in a mammal in need thereof, said method comprising administering effective amounts of a pharmaceutically acceptable composition containing at least one probiotic microorganism strain comprising Pediococcus for a time sufficient to ameliorate, reduce or treat at least one symptom, sign, or marker of irritable bowel syndrome, inflammatory bowel disease or gastritis.
    Type: Application
    Filed: June 10, 2011
    Publication date: December 13, 2012
    Inventor: Stephen F. Olmstead
  • Publication number: 20110091431
    Abstract: Compositions, methods, etc., comprising Pediococcus and at least one other probiotic microbial organism that reduce one or more symptoms of an autism spectrum disorder such as autism. The compositions can be used, for example, as dietary supplements, food additives, and pharmaceutical preparations.
    Type: Application
    Filed: October 8, 2010
    Publication date: April 21, 2011
    Applicant: PROTHERA, INC.
    Inventor: STEPHEN F. OLMSTEAD
  • Publication number: 20090202516
    Abstract: Orally administered physiologically acceptable anti-biofilm compositions comprising enzymes and if desired additional components such as antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of gastrointestinal biofilm infections, and associated systemic symptoms caused by biofilms associated microorganisms within the gastrointestinal tract. Methods of identification, preparation and use of such physiologically acceptable anti-biofilm compositions are also provided.
    Type: Application
    Filed: February 9, 2009
    Publication date: August 13, 2009
    Applicant: ProThera, Inc.
    Inventor: Stephen F. Olmstead